KR20220080205A - 천연 병용 호르몬 대체 제형 및 요법 - Google Patents

천연 병용 호르몬 대체 제형 및 요법 Download PDF

Info

Publication number
KR20220080205A
KR20220080205A KR1020227018561A KR20227018561A KR20220080205A KR 20220080205 A KR20220080205 A KR 20220080205A KR 1020227018561 A KR1020227018561 A KR 1020227018561A KR 20227018561 A KR20227018561 A KR 20227018561A KR 20220080205 A KR20220080205 A KR 20220080205A
Authority
KR
South Korea
Prior art keywords
progesterone
estradiol
pharmaceutical formulation
fatty acid
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018561A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 에이. 베르닉
재니스 루이스 카카케
피터 에이치.알. 페르시카너
네다 이라니
줄리아 엠. 아마디오
프레드릭 디. 산시리오
Original Assignee
쎄러퓨틱스엠디, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49756456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220080205(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/684,002 external-priority patent/US8633178B2/en
Application filed by 쎄러퓨틱스엠디, 인코퍼레이티드 filed Critical 쎄러퓨틱스엠디, 인코퍼레이티드
Priority to KR1020237003285A priority Critical patent/KR20230021170A/ko
Publication of KR20220080205A publication Critical patent/KR20220080205A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227018561A 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법 Ceased KR20220080205A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237003285A KR20230021170A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261661302P 2012-06-18 2012-06-18
US61/661,302 2012-06-18
US201261662265P 2012-06-20 2012-06-20
US61/662,265 2012-06-20
US13/684,002 2012-11-21
US13/684,002 US8633178B2 (en) 2011-11-23 2012-11-21 Natural combination hormone replacement formulations and therapies
US13/843,428 2013-03-15
US13/843,428 US9301920B2 (en) 2012-06-18 2013-03-15 Natural combination hormone replacement formulations and therapies
KR1020217027152A KR20210107915A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
PCT/US2013/046445 WO2013192251A1 (en) 2012-06-18 2013-06-18 Natural combination hormone replacement formulations and therapies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217027152A Division KR20210107915A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003285A Division KR20230021170A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법

Publications (1)

Publication Number Publication Date
KR20220080205A true KR20220080205A (ko) 2022-06-14

Family

ID=49756456

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227018561A Ceased KR20220080205A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020237003285A Ceased KR20230021170A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020217027152A Ceased KR20210107915A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020157001189A Active KR102177782B1 (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020207032034A Ceased KR20200128214A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020237003285A Ceased KR20230021170A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020217027152A Ceased KR20210107915A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020157001189A Active KR102177782B1 (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법
KR1020207032034A Ceased KR20200128214A (ko) 2012-06-18 2013-06-18 천연 병용 호르몬 대체 제형 및 요법

Country Status (14)

Country Link
US (14) US9301920B2 (https=)
EP (2) EP2861072B1 (https=)
JP (3) JP6334519B2 (https=)
KR (5) KR20220080205A (https=)
AU (4) AU2013277236B2 (https=)
BR (1) BR112014031910B1 (https=)
CA (1) CA2876977A1 (https=)
ES (1) ES2967709T3 (https=)
IL (1) IL236358B (https=)
MX (2) MX383208B (https=)
PL (1) PL2861072T3 (https=)
PT (1) PT2861072T (https=)
RU (2) RU2019142696A (https=)
WO (1) WO2013192251A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
EP3909586A1 (en) * 2012-06-18 2021-11-17 TherapeuticsMD, Inc. Soluble estradiol capsule for vaginal insertion
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015237243A1 (en) * 2014-03-28 2016-09-29 Therapeuticsmd, Inc. Progesterone formulations
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10467382B2 (en) * 2014-11-14 2019-11-05 Brazen Incorporated Conceivable basal body temperatures and menstrual cycle
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US20170281647A1 (en) * 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
MX2019006513A (es) * 2016-12-05 2019-08-14 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de hormonas de combinacion natural.
US20180280410A1 (en) * 2017-04-03 2018-10-04 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
EP4410375A3 (en) * 2018-09-11 2024-11-06 iTeos Belgium SA Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
AU2020256291A1 (en) * 2019-03-29 2021-11-18 Martin DOORBAR Eva segmented intravaginal rings containing progesterone
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2022100558A (ja) 2020-12-24 2022-07-06 日本碍子株式会社 ハニカムフィルタ
US11298375B2 (en) * 2021-10-12 2022-04-12 Terry Earl Brady Halogenated fullerene functionalized as a biocidal and chemotactic spermicide to vaginally harbor and neutralize spermatozoa for use as a safe and effective contraceptive

Family Cites Families (1172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1967351A (en) 1930-10-06 1934-07-24 President And Board Hormone and process of obtaining the same
US2232438A (en) 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
GB452238A (en) 1934-08-24 1936-08-19 Chem Ind Basel Process for purifying progesterone preparations
US2379832A (en) 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
US2649399A (en) 1951-02-01 1953-08-18 Ayerst Mckenna & Harrison Conjugated oestrogenic quaternary ammonium salts and their preparation
GB720561A (en) 1952-04-17 1954-12-22 Frederick Victor Wells Improvements in preparations for application to the hair and scalp
GB848881A (en) 1955-12-27 1960-09-21 Upjohn Co Improvements in or relating to hormone compositions and the preparation thereof
GB874368A (en) 1957-12-09 1961-08-02 Irwin Irville Lubowe Improvements in anti-seborrheic and scalp preparations
FR1368727A (fr) 1961-05-04 1964-08-07 Roussel Uclaf Dérivés de l'estradiol et procédé de préparation
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3755575A (en) 1965-01-26 1973-08-28 Squibb & Sons Inc Pharmaceutical compositions
FR5519M (https=) 1966-06-07 1967-11-06
US3478070A (en) 1967-12-26 1969-11-11 American Home Prod Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof
GB1261348A (en) 1968-04-02 1972-01-26 Leo Ab Treatment of hair and scalp and compositions therefor
US3755573A (en) 1970-07-10 1973-08-28 Warner Lambert Co Fertility control empoying quinestrol and quingestanol acetate
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3903880A (en) 1972-08-17 1975-09-09 Alza Corp Intrauterine device for managing the reproductive process
US3923997A (en) 1971-05-11 1975-12-02 Rhodia Process for repelling dogs and cats from a selected area or from each other using {65 -n-alkyl-{65 -butyrolactones and {67 -n-alkyl-{67 -valerolactones
US3729566A (en) 1971-05-25 1973-04-24 Upjohn Co Rodent sterilant process
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4016251A (en) 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US3971367A (en) 1972-12-27 1976-07-27 Alza Corporation Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4014987A (en) 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
NL7506407A (nl) 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4154820A (en) 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4310510A (en) 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4393871A (en) 1977-06-27 1983-07-19 Vli Corporation Vaginal device
GB1589946A (en) 1977-12-14 1981-05-20 Kali Chemie Pharma Gmbh Enterally absorbable preparations and process for the production thereof
US4215691A (en) 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4732763A (en) 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4384096A (en) 1979-08-27 1983-05-17 The Dow Chemical Company Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems
US4372951A (en) 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US4402695A (en) 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
GB2079158B (en) 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4423151A (en) 1981-09-24 1983-12-27 Peter S. Brune Process for preparation of control for use in estrogen receptor tests
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4610687A (en) 1984-08-06 1986-09-09 Board Of Trustees Operating Michigan State University Method for breeding control in female bovines
DE3510555A1 (de) 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen Estriolester
US4816257A (en) 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
US5145682A (en) 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4908389A (en) 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US6139868A (en) 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
CN1021196C (zh) 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4876249A (en) 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4865848A (en) 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4942158A (en) 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
HU210549B (en) 1988-10-27 1995-05-29 Schering Ag Process for producing transdermally applicable pharmaceutical composition containing gestodene
US5164416A (en) 1989-02-03 1992-11-17 Lintec Corporation Transdermal therapeutic formulation containing a limonene
JP2651616B2 (ja) 1989-02-03 1997-09-10 リンテック株式会社 経皮吸収製剤
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5059426A (en) 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
JP2910857B2 (ja) 1989-04-04 1999-06-23 ニチバン株式会社 プロスタグランジンｅ１経皮吸収製剤
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE69010076T2 (de) 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
DE69007886T2 (de) 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE3933460A1 (de) 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
AU653156B2 (en) 1990-06-14 1994-09-22 Dermamed Transdermal administration to humans and animals
DE4104385C1 (https=) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
FR2673840A1 (fr) 1991-03-14 1992-09-18 Lvmh Rech Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute.
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
GB9113726D0 (en) 1991-06-25 1991-08-14 Inst Of Animal Physiology And Artificial animal foster mothers
US5653983A (en) 1991-07-19 1997-08-05 Lvmh Recherche Compositions for the pigmentation of the skin or of the hair containing an extract of Marrubium vulgare, the process for it's manufacture and it's
US5676968A (en) 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
CA2125282C (en) 1991-12-05 1999-08-31 Jens-Christian Wunderlich Pharmaceutically applicable nanosol and process for preparing the same
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5453279A (en) 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5295945A (en) 1992-08-03 1994-03-22 Beth Israel Hospital Assoc. Inc. Garment and method for positioning and securing a radioactive implant internally within the female genital organs
FR2695561B1 (fr) 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
EP0663071B1 (en) 1992-09-28 2003-12-03 Biex, Inc. Method for prediction of premature labor
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
DE69332954D1 (de) 1992-10-21 2003-06-12 Gynetech Lab Inc Abgabesystem bestehend aus einem vaginaschwamm
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
FR2699406B1 (fr) 1992-12-21 1995-03-10 Commissariat Energie Atomique Films à base de copolymères, leurs applications dans des systèmes transdermiques et leurs procédés de préparation.
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5843979A (en) 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
SE9301171D0 (sv) 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5595970A (en) 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
DE4329242A1 (de) 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
CA2165802A1 (en) 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
DE4341444C2 (de) 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
DE4344463A1 (de) 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4400770C1 (de) 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
ATE246909T1 (de) 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2717689B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène.
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
CA2187023A1 (en) 1994-04-13 1995-10-26 Steven Andrew Giannos Temporally controlled drug delivery systems
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
CA2188566A1 (en) 1994-05-05 1995-11-16 Conrad Winters Topical polymeric drug delivery system
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5709844A (en) 1994-06-09 1998-01-20 The Regents Of The University Of California Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia
US5869084A (en) 1994-06-20 1999-02-09 K-V Pharmaceuticals Co. Multi-vitamin and mineral supplements for women
JPH11505504A (ja) 1994-06-27 1999-05-21 イオニックス・コーポレーション ホウ素を含有するホルモン類似体及びホルモン受容体を有する細胞をイメージング若しくは殺すためにこれらを使用する方法
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
US5735801A (en) 1994-08-25 1998-04-07 Caillouette; James C. Estrogen or estradiol need determination by vaginal acidity determination
US5916176A (en) 1994-08-25 1999-06-29 Caillouette; James C. Estrogen or estradiol need determination by vaginal or urethral acidity determination
US5827200A (en) 1997-01-27 1998-10-27 Caillouette; James C. Method and apparatus for detecting amine producing organisms in the vagina
US5762614A (en) 1994-08-25 1998-06-09 Caillouette; James C. Estrogen or estradiol need determination by vaginal acidity determination
US6402705B1 (en) 1994-08-25 2002-06-11 James C. Caillouette Body moisture test apparatus and method
WO1996008229A2 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US6716454B2 (en) 1994-09-23 2004-04-06 Laboratorie Innothera, Société Anonyme Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof
IL115445A (en) 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
US5820878A (en) 1994-11-18 1998-10-13 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5885974A (en) 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
FR2728463A1 (fr) 1994-12-21 1996-06-28 Lhd Lab Hygiene Dietetique Systeme transdermique d'administration simultanee de plusieurs principes actifs
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
DE19500662C2 (de) 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
US5516528A (en) 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
FR2729854A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5565199A (en) 1995-02-07 1996-10-15 Page; Elliot W. Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants
US5609617A (en) 1995-02-21 1997-03-11 C. Norman Shealy Method for enhancement of dehydroepiandrosterone
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5693335A (en) 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US5679573A (en) 1995-07-27 1997-10-21 Abbott Laboratories Stabilized aqueous steroid immunoassay standards with cyclodextrins
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5567831A (en) 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US5840327A (en) 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
FR2739032B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US6551611B2 (en) 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5922349A (en) 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
FR2739558B1 (fr) 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2739559B1 (fr) 1995-10-05 1997-11-28 Innothera Lab Sa Gel pour hormonotherapie locale de la secheresse vaginale
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
GB9522403D0 (en) 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5770176A (en) 1995-12-08 1998-06-23 Chiron Diagnostics Corporation Assays for functional nuclear receptors
DE19549264A1 (de) 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
DE19548332A1 (de) 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
EP0785212A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
EP0785211A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
NZ286492A (en) 1996-05-01 1998-02-26 Dec International Nz Ltd Subst Intra vaginal devices for synchronising oestrus of animals is made up of cured silicone rubber material with 5% by weight of progesterone
US6040340A (en) 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5962445A (en) 1996-05-09 1999-10-05 Amrad Operations Pty Ltd. Treatment of asthma and airway diseases
WO1997043989A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
DE19629468A1 (de) 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
EP1806131A3 (en) 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6227202B1 (en) 1996-09-03 2001-05-08 Maulana Azad Medical College Method of organogenesis and tissue regeneration/repair using surgical techniques
WO1998010293A1 (en) 1996-09-06 1998-03-12 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
ES2260802T3 (es) 1996-10-18 2006-11-01 Arizona Chemical Company Geles de poliamida terminada en esteres.
JP2001503749A (ja) 1996-10-30 2001-03-21 セラテック・インコーポレーテッド 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
US20060014728A1 (en) 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
DE19654609A1 (de) 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
KR100215027B1 (ko) 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
US20010023261A1 (en) 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
FR2759292B1 (fr) 1997-02-10 2000-08-11 Cird Galderma Utilisation de retinoides en tant qu'agents induisant la pigmentation
DE19705229C2 (de) 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
FR2760639B1 (fr) 1997-03-14 2000-09-22 Innothera Lab Sa Association therapeutique mineralo-vitaminique sous forme de preparation unitaire liquide buvable
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
CN1193718C (zh) 1997-05-28 2005-03-23 英特瑞格 猪用阴道内器具及其使用方法
WO1998058633A2 (en) 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors
US6039968A (en) 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19728517C2 (de) 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung
DE19728516C2 (de) 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US8765177B2 (en) 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040234606A1 (en) 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
GB9720470D0 (en) 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
WO1999022680A1 (en) 1997-11-03 1999-05-14 Deschutes Medical Products, Inc. Pessary with medicated cartridge
CA2310632A1 (en) 1997-11-19 1999-05-27 Humanetics Corporation Use of .delta.5-androstene-3.beta.-ol-7,17-dione in the treatment of lupus erythematosus
US5891868A (en) 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6503896B1 (en) 1997-12-24 2003-01-07 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
FR2774291B1 (fr) 1998-02-03 2000-04-21 Innothera Lab Sa Specialite pharmaceutique sous forme galenique unitaire de comprimes a croquer ou a sucer, comprenant comme principe actif du fer element
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6001846A (en) 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
DE19807791A1 (de) 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
US6028057A (en) 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
CA2293605A1 (en) 1998-04-11 1999-10-21 Paolo Luca Maria Giorgetti Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
US20030040790A1 (en) 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6190693B1 (en) 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
FR2777783A1 (fr) 1998-04-24 1999-10-29 Innothera Lab Sa Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses
FR2777784B1 (fr) 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6277418B1 (en) 1998-06-02 2001-08-21 Baylor College Of Medicine Corn extract contraceptive
DE69919863T8 (de) 1998-06-03 2005-12-15 Ardana Bioscience Ltd. Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
DE19825591A1 (de) 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
NZ330726A (en) 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
ATE399565T1 (de) 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
DE19834931A1 (de) 1998-07-28 2000-02-24 Jenapharm Gmbh Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie
DE19834007C1 (de) 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
US20070015698A1 (en) 1998-07-30 2007-01-18 United States Of America As Represented By The Secretary Of Health Treatment of skin, and wound repair, with thymosin beta 4
US20030181353A1 (en) 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
AU5675099A (en) 1998-08-17 2000-03-06 William E. Trout Use of zeranol to modulate reproductive cycles
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20020169205A1 (en) 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
AU759016B2 (en) 1998-10-05 2003-04-03 Penn State Research Foundation, The Compositions and methods for enhancing receptor-mediated cellular internalization
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
GB9828480D0 (en) 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
NZ513208A (en) 1999-02-05 2003-05-30 Cipla Ltd Topical sprays comprising a film forming composition
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6080118A (en) 1999-02-25 2000-06-27 Blythe; Cleveland Vaginal probe and method of using same
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911799A1 (de) 1999-03-17 2000-09-28 Lohmann Therapie Syst Lts Sammelpackung zur Entnahme von befüllten Beuteln in vorgebener Reihenfolge
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6974569B2 (en) 1999-05-03 2005-12-13 The Procter & Gamble Company Shampoos providing a superior combination anti-dandruff efficacy and condition
US6451300B1 (en) 1999-05-03 2002-09-17 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers
US6649155B1 (en) 1999-05-03 2003-11-18 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing certain cationic polymers
KR20020011985A (ko) 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
DE60006380T2 (de) 1999-05-13 2004-05-13 Hisamitsu Pharmaceutical Co., Inc., Tosu Pflaster
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US6645947B1 (en) 1999-05-20 2003-11-11 Chitogenics, Inc. Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
PL351948A1 (en) 1999-06-04 2003-07-14 Alza Corp Implantable gel compositions and method of making thereof
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
TR200200406T2 (tr) 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
GB9914648D0 (en) 1999-06-24 1999-08-25 Univ Birmingham Control of infra-ocular pressure
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6303132B1 (en) 1999-07-16 2001-10-16 Ardell H. Nelson Administering progesterone using EMU oil
KR20010010393A (ko) 1999-07-20 2001-02-05 김윤 소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물
NZ337318A (en) 1999-08-18 2002-07-26 Interag Dispensing apparatus for dispensing same or different materials for at least two reservoirs
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013836A1 (en) 1999-08-26 2001-03-01 West Virginia University Cervical agent delivery system
SK287634B6 (sk) 1999-08-31 2011-04-05 Bayer Schering Pharma Aktiengesellschaft Farmaceutická kompozícia obsahujúca drospirenón a etinylestradiol a farmaceutický prípravok
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CA2384679A1 (en) 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6436633B1 (en) 1999-10-22 2002-08-20 The Pennsylvania State University Human xenografts for microbicide testing and anatomical modeling
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AUPQ419099A0 (en) 1999-11-23 1999-12-16 Ko, Thomas Sai Ying Novel compositions and methods
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US20020012710A1 (en) 1999-11-29 2002-01-31 Rimonest Ltd. Pomegranate products useful in improving health and methods of use thereof
US6708822B1 (en) 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US20010032125A1 (en) 1999-12-20 2001-10-18 Sundeep Bhan Activation of coupons based on quiz or questionnaire
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
FR2804603B1 (fr) 2000-02-04 2004-01-23 Rhodia Chimie Sa Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
KR20080049148A (ko) 2000-02-16 2008-06-03 벤트레이 파마슈티칼스, 인코포레이티드 약학적 조성물
CA2406871A1 (en) 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
US7459445B2 (en) 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20010034340A1 (en) 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US20040176336A1 (en) 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
RU2251405C2 (ru) 2000-03-27 2005-05-10 Шотт Глас Композиции для косметических препаратов, средств личной гигиены, компонентов очищающего действия, пищевых добавок, способы их получения и применения
IL135335A (en) 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids
ATE334682T1 (de) 2000-03-31 2006-08-15 Us Gov Health & Human Serv Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
BR0109983A (pt) 2000-04-12 2003-02-25 Schering Ag Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US8119138B2 (en) 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US20030171343A1 (en) 2000-05-31 2003-09-11 Yoshiko Furukawa Percutaneous absorption type steroid preparation for external use
GB0015617D0 (en) 2000-06-26 2000-08-16 Vectura Ltd Improved preparations for dermal delivery of active substances
US20030114420A1 (en) 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6740333B2 (en) 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
ATE290372T1 (de) 2000-07-24 2005-03-15 Upjohn Co Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
US20020119174A1 (en) 2000-07-26 2002-08-29 Gardlik John Michael Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
KR100765670B1 (ko) 2000-09-19 2007-10-10 브리스톨-마이어스스퀴브컴파니 융합된 헤테로시클릭 숙신이미드 화합물 및 그의 유사체,핵 호르몬 수용체 기능의 조절제
EE200300109A (et) 2000-09-20 2005-04-15 Nycomed Pharma As Protsess vedela emulsioonkompositsiooni valmistamiseks ja emulsiooni kontsentraadi valmistamiseks, farmatseutiline kompositsioon, emulsiooni kontsentraat, komplekt ja emulsioonkompositsioon
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
WO2002032431A1 (fr) 2000-10-16 2002-04-25 Hisamitsu Pharmaceutical Co., Inc. Compositions pour preparations externes
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
WO2002036144A1 (en) 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US6328987B1 (en) 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
US20030113268A1 (en) 2000-11-10 2003-06-19 Mina Buenafae Degradation-resistant glucocorticosteroid formulations
US6605605B2 (en) 2000-11-13 2003-08-12 Milton Hammerly Estrogenic substances combined with cruciferous indole compounds
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
DE60113290D1 (de) 2000-11-17 2005-10-13 Warner Lambert Co Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
FR2816838B1 (fr) 2000-11-17 2004-12-03 Oreal Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US7867990B2 (en) 2000-12-14 2011-01-11 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them
US7018992B2 (en) 2000-12-15 2006-03-28 Novo Nordisk A/S Hormone composition
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20020151530A1 (en) 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
EP1351678A2 (en) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20020197286A1 (en) 2001-01-16 2002-12-26 Jane Brandman Method for preventing and treating skin aging
FR2820320B1 (fr) 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7381427B2 (en) 2001-02-09 2008-06-03 Mickey Miller Seborrheic keratosis treatment
NZ509894A (en) 2001-02-09 2002-11-26 Interag A "T" or "Y" shaped intravaginal device suitable for delivery of pharmaceuticals such as progesterone
US7303763B2 (en) 2001-02-12 2007-12-04 Watson Laboratories, Inc. Compositions for conjugated estrogens and associated methods
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002102325A2 (en) 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
EA200301022A1 (ru) 2001-03-16 2004-02-26 Уайт Гормональная заместительная терапия
FR2828102B1 (fr) 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
CA2443128A1 (en) 2001-03-30 2002-10-10 Debra A. Martin Transdermal delivery of pergolide
WO2002078604A2 (en) 2001-03-30 2002-10-10 Elan Transdermal Technologies, Inc. Transdermal delivery of bioactive material
US20020142941A1 (en) 2001-03-30 2002-10-03 Pro Duct Health, Inc. Intraductal treatment targeting methylated promoters in breast cancer
US20040131670A1 (en) 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US6860859B2 (en) 2001-04-20 2005-03-01 Monsanto Technology Llc Apparatus and method for detection of estrus and/or non-pregnancy
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20050209208A1 (en) 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20120322779A9 (en) 2001-04-25 2012-12-20 Rhonda Voskuhl Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US8658627B2 (en) 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
AU2002309919B2 (en) 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
DK1390040T3 (da) 2001-05-18 2007-04-23 Pantarhei Bioscience Bv Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
JP4865958B2 (ja) 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
IL159415A0 (en) 2001-06-18 2004-06-01 Noven Pharma Enhanced drug delivery in transdermal systems
US20020193758A1 (en) 2001-06-18 2002-12-19 Sca Hygiene Products Ab Product
US7094228B2 (en) 2001-07-31 2006-08-22 Zars, Inc. Methods and formulations for photodynamic therapy
EP1411922A1 (en) 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
US6911438B2 (en) 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation
DE10146541A1 (de) 2001-09-21 2003-04-17 Kade Pharma Fab Gmbh Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung
US7393696B2 (en) 2001-09-28 2008-07-01 Aspenbio Pharma, Inc. Bovine pregnancy test
IL161105A0 (en) 2001-09-29 2004-08-31 Solvay Pharm Gmbh Estrogen/gestagen combination preparation and application thereof
WO2003028667A2 (en) 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR026386A1 (es) 2001-10-24 2003-02-12 Massara Julio Eduardo Un dispositivo intravaginal que contiene progesterona, util como inductor de celo en bovinos productores de carne y leche, y el procedimiento paraprepararlo
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
US20070196415A1 (en) 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
CA2467237C (en) 2001-11-15 2011-09-20 Herman Jan Tijmen Coelingh Bennink Method of preventing or treating benign gynaecological disorders
EP1458361A4 (en) 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
DE10159120B4 (de) 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
ES2188426B1 (es) 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
TWI332400B (en) 2001-12-14 2010-11-01 Solvay Pharm Gmbh Preformulation for the tableting of natural mixtures of conjugated estrogens
US7329654B2 (en) 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
DE60228330D1 (de) 2001-12-19 2008-09-25 Bristol Myers Squibb Co Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
US7011846B2 (en) 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
US6962908B2 (en) 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US6901278B1 (en) 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US20060052341A1 (en) 2002-02-08 2006-03-09 Brian Cornish Control of a biological function
NZ517094A (en) 2002-02-08 2005-03-24 Advanced Animal Technology Ltd Improvements in and relating to substance delivery device
GB0203276D0 (en) 2002-02-12 2002-03-27 Novartis Ag Organic compounds
US20030219402A1 (en) 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
DE10206390A1 (de) 2002-02-15 2003-08-28 Bionorica Ag Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten
BR0215613A (pt) 2002-02-21 2004-12-07 Schering Ag Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12
US20030175333A1 (en) 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
US7741116B2 (en) 2002-03-06 2010-06-22 University Of Cincinnati Surgical device for skin therapy or testing
JP2005526064A (ja) 2002-03-11 2005-09-02 シエーリング アクチエンゲゼルシャフト 受精能制御およびホルモン置換療法における使用のためのプロゲステロン受容体調整活性を有する５−｛２−ヒドロキシ−３−１−（３−トリフルオロメチルフェニル）−シクロプロピル−プロピオニルアミノ｝−フタリドおよび関連化合物
ATE336252T1 (de) 2002-03-11 2006-09-15 Janssen Pharmaceutica Nv Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
CA2478165A1 (en) 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Sulfatase inhibiting progestogen-only contraceptive regimens
EP1485103A1 (en) 2002-03-11 2004-12-15 Janssen Pharmaceutica N.V. Sulfatase inhibiting continuous progestogen contraceptive regimens
EP1482946A1 (en) 2002-03-14 2004-12-08 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
DE10211832A1 (de) 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion
FR2837100B1 (fr) 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
AU2003226021B2 (en) 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles
US7300926B2 (en) 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
US20030191096A1 (en) 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
WO2003082254A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
US20050214384A1 (en) 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
DE10218109A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
HK1079997A1 (zh) 2002-04-26 2006-04-21 舍林股份公司 治疗接受激素替代疗法之妇女中的高血压的方法
CA2484173A1 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
US20060083778A1 (en) 2002-05-03 2006-04-20 Dean Allison Controlled release compositions of estradiol metabolites
US7727720B2 (en) 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US8591951B2 (en) 2002-05-15 2013-11-26 Joachim B. Kohn Tri-block copolymers for nanosphere-based drug delivery
US6821524B2 (en) 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
US6943021B2 (en) 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
AU2003274941A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
US20040048900A1 (en) 2002-06-17 2004-03-11 Pamela Flood Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects
US20050186141A1 (en) 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2003251636B2 (en) 2002-07-25 2009-10-22 Bayer Schering Pharma Aktiengesellschaft Composition containing an androgenous 11beta-halogen steroid and a progestational hormone, and male contraceptive based on said composition
US6960337B2 (en) 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
TR200201966A2 (tr) 2002-08-07 2004-02-23 Edko Pazarlama Tanitim Ti̇caret Li̇mi̇ted Şi̇rketi̇ Farmasötik terkip.
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
ATE452645T1 (de) 2002-08-20 2010-01-15 Univ Singapore Phytoprogestogenen extrakten aus rhizoma ligusticum chuanxiong und ihre verwendungszwecke
CN1678324A (zh) 2002-08-28 2005-10-05 罗伯特·卡斯珀 雌激素替代治疗方案
WO2004022033A1 (en) 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ES2338782T3 (es) 2002-09-05 2010-05-12 Pantarhei Bioscience B.V. Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
US6967194B1 (en) 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US7458982B2 (en) 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10247399A1 (de) 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
FR2845597B1 (fr) 2002-10-11 2005-03-11 Innothera Lab Sa Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer
US20040146894A1 (en) 2002-10-14 2004-07-29 Warrington Janet A. Methods of diagnosing and treating stress urinary incontinence
GB0224415D0 (en) 2002-10-21 2002-11-27 Medical Res Council Compositions
AU2003274823A1 (en) 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060193789A1 (en) 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
DE10249853A1 (de) 2002-10-25 2004-05-13 Liedtke, Rainer K., Dr. Pflasterartige Chip-Systeme zur thermodynamischen Kontrolle topisch dermaler und transdermaler Systeme
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060247216A1 (en) 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040087564A1 (en) 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US20040138103A1 (en) 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
US20040093261A1 (en) 2002-11-08 2004-05-13 Vivek Jain Automatic validation of survey results
US20040089308A1 (en) 2002-11-13 2004-05-13 Welch Robert A. Cervical ring to deliver medication
US20040097468A1 (en) 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7674783B2 (en) 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
AU2003291872A1 (en) 2002-12-04 2004-06-23 Inrs (Institut National De Recherche Scientifique) An exopolysaccharides delivery system for active molecules
FR2848112B1 (fr) 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
ATE400270T1 (de) 2002-12-18 2008-07-15 Ferrer Int Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
FR2849380A1 (fr) 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
WO2004060447A2 (en) 2002-12-31 2004-07-22 Ultra-Sonic Technologies, L.L.C. Transdermal delivery using encapsulated agent activated by ultrasound and/or heat
FR2849597B1 (fr) 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US20090318558A1 (en) 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20060194775A1 (en) 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
WO2004073696A1 (de) 2003-02-21 2004-09-02 Schering Ag Uv-stabiles transdermales pflaster
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US6956099B2 (en) 2003-03-20 2005-10-18 Arizona Chemical Company Polyamide-polyether block copolymer
US20040191207A1 (en) 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
ATE515493T1 (de) 2003-03-31 2011-07-15 Council Scient Ind Res Mercaptophenylnaphthylmethan-derivate und deren herstellung
AU2004233997C1 (en) 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
WO2004097002A2 (en) 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
BRPI0409860A (pt) 2003-04-29 2006-05-16 Akzo Nobel Nv processo de solidificação anti-solvente
US20040219124A1 (en) 2003-05-01 2004-11-04 Gupta Shyam K. Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US7925519B2 (en) 2003-05-20 2011-04-12 Medencentive, Llc Method and system for delivery of healthcare services
DK1624878T3 (da) 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
US20040243437A1 (en) 2003-05-30 2004-12-02 Grace Joseph P. Compensated electronic consults
US7668735B2 (en) 2003-05-30 2010-02-23 Mdrxdirect Inc. Compensated electronic consults
US20090227025A1 (en) 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
US20040253319A1 (en) 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
DK1820494T3 (da) 2003-06-13 2010-05-25 Skendi Finance Ltd Mikropartikler bestående af estradiol og cholesterol
EP1488785A1 (de) 2003-06-18 2004-12-22 B. Braun Melsungen Ag Ölemulsion zur postnatalen Hormonsubstitution
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
CN1812746B (zh) 2003-06-27 2011-07-06 孕体有限公司 用于阻塞体腔和/或用于递送治疗剂的方法和装置
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
AU2004255340B2 (en) 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
AU2004257674A1 (en) 2003-07-11 2005-01-27 Macrochem Corporation Pharmaceutical compositions for topical application
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
JP5651279B2 (ja) 2003-09-03 2015-01-07 ミスコン トレイディング エス．エー． 子宮内膜症の処置のための方法
SI1663185T1 (sl) 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
JP2005104862A (ja) 2003-09-29 2005-04-21 Meiji Milk Prod Co Ltd 加齢黄斑変性治療剤
WO2005030175A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
ES2933479T3 (es) 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
US7247625B2 (en) 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
HUP0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1677740A2 (en) 2003-10-16 2006-07-12 The Administrators Of The Tulane Educational Fund Methods and compositions for treating cancer
US8124118B2 (en) 2003-10-22 2012-02-28 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery
EP2441465B1 (en) 2003-10-24 2014-01-15 Nora Therapeutics, Inc. Compositions and methods for healthy pregnancy
US20050101579A1 (en) 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
ATE410171T1 (de) 2003-11-14 2008-10-15 Warner Chilcott Co Inc Graduierte östrogen-kontrazeptiva
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20050186183A1 (en) 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
CN1889994A (zh) 2003-12-10 2007-01-03 艾克若克斯Dds有限公司 伴随透皮或局部药物输送的不希望的效果的治疗方法
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
US20070191319A1 (en) 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
CA2550811C (en) 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
US20080069791A1 (en) 2003-12-29 2008-03-20 Universitaetsklinikum Muenster Means for stimulation and activation of hair growth by il-15
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
ES2702607T3 (es) 2004-01-07 2019-03-04 E L Man Corporation Composición cosmética y método de retardo del crecimiento del vello
US20060084704A1 (en) 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US20050271597A1 (en) 2004-02-13 2005-12-08 Keith Alec D Prostate hypertrophy treatment composition and method
HRP20090363T1 (hr) 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20050196434A1 (en) 2004-03-04 2005-09-08 Brierre Barbara T. Pharmaceutical composition and method for the transdermal delivery of magnesium
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
BRPI0508612A (pt) 2004-03-10 2007-08-14 Schering Aktiengellschaft composições compreendendo drospirenona dispersa molecularmente
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
US20050222106A1 (en) 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
CA2564341A1 (en) 2004-04-07 2005-10-27 Dermatrends, Inc. Transdermal delivery system for use with basic permeation enhancers
US20050228692A1 (en) 2004-04-08 2005-10-13 Hodgdon Darren W Incentive based health care insurance program
US20050228718A1 (en) 2004-04-13 2005-10-13 Pop Insights Inc. Point of purchase research device
US20050239747A1 (en) 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
US20050239758A1 (en) 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
RU2275930C2 (ru) 2004-04-26 2006-05-10 ООО "РусГен" Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20050250746A1 (en) 2004-05-06 2005-11-10 Matthew Iammatteo Premenstrual dysphoric disorder medication
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
FR2870125B1 (fr) 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
US7899527B2 (en) 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US7101342B1 (en) 2004-05-24 2006-09-05 Caillouette James C Detection of menopause status and treatment thereof
EP1755618A1 (en) 2004-05-26 2007-02-28 Wyeth a Corporation of the State of Delaware Compositions and methods for treatment of premenstrual dysphoric disorder
US20070196453A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
WO2005120517A1 (en) 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
DE102004028284A1 (de) 2004-06-11 2006-01-05 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin
US7485666B2 (en) 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7235563B2 (en) 2004-06-21 2007-06-26 Bristol-Myers Squibb Company Spirocyclic compounds useful as modulators of nuclear hormone receptor function
US20060009428A1 (en) 2004-07-07 2006-01-12 Wyeth Cyclic progestin regimens and kits
FR2873585B1 (fr) 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
CA2575906C (en) 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060040904A1 (en) 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7879830B2 (en) 2004-09-02 2011-02-01 Wiley Teresa S Hormone replacement composition and method
US20070167418A1 (en) 2004-09-07 2007-07-19 Ferguson Steven W Progesterone/testosterone cream for erectile dysfunction
AU2005281393B2 (en) 2004-09-09 2012-01-12 Virbac (Australia) Pty Ltd Trace elements
AR043476A1 (es) 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US20080220069A1 (en) 2004-09-13 2008-09-11 Pr Pharmaceuticals, Inc. Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
US20070254314A1 (en) 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
ATE514700T1 (de) 2004-09-20 2011-07-15 Janssen Pharmaceutica Nv Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
US20060062758A1 (en) 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
ES2310293T3 (es) 2004-09-27 2009-01-01 Pantarhei Bioscience B.V. Tratamiento o prevencion de sangrados no programados en mujeres bajo medicacion que contiene progestogeno.
US20060121102A1 (en) 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
WO2006051818A1 (ja) 2004-11-10 2006-05-18 Hisamitsu Pharmaceutical Co., Inc. 外用製剤及び貼付剤
US20060106004A1 (en) 2004-11-12 2006-05-18 Brody Steven A Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US8121886B2 (en) 2004-12-03 2012-02-21 Ryma Technology Solutions Inc. Confidence based selection for survey sampling
US7465587B2 (en) 2004-12-03 2008-12-16 Genzyme Corporation Diagnostic assay device
AT501408B1 (de) 2004-12-07 2011-03-15 Physikalisches Buero Steinmueller Gmbh Biologische oberflächen
CA2588566A1 (en) 2004-12-17 2006-06-22 Bionovo, Inc. Estrogenic extracts of morus alba and uses thereof
US20060134188A1 (en) 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006081518A2 (en) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
ITMI20050262A1 (it) 2005-02-21 2006-08-22 Carlo Ghisalberti Sostanze composizioni e metodi di trattamento dell'alopecia
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US7405186B2 (en) 2005-03-25 2008-07-29 Chemsil Silicones, Inc. Lubricant compositions, condom products and methods of making same
JP5256425B2 (ja) 2005-04-08 2013-08-07 リングアル コンセグナ ピーティーワイ エルティーディー 口腔送達システム
EP1868590A4 (en) 2005-04-13 2012-08-29 Unimed Pharmaceuticals Inc PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US7767656B2 (en) 2005-04-25 2010-08-03 Molly S Shoichet Blends of temperature sensitive and anionic polymers for drug delivery
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US8048017B2 (en) 2005-05-18 2011-11-01 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
ZA200711040B (en) 2005-06-03 2009-04-29 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2610767C (en) 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol
CA2612380C (en) 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
CN101232869B (zh) 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
US20070004693A1 (en) 2005-06-16 2007-01-04 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
ES2399105T3 (es) 2005-06-29 2013-03-25 Warner Chilcott Company, Llc Anticonceptivo estrogénico cuadrifásico graduado de manera continua
US20070010550A1 (en) 2005-07-08 2007-01-11 The Board Of Regents Of The University Of Texas Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia
US20070014839A1 (en) 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
DE102005034498A1 (de) 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
US8195403B2 (en) 2005-07-21 2012-06-05 The Invention Science Fund I, Llc Selective resonance of bodily agents
PE20070341A1 (es) 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
US20070027107A1 (en) 2005-07-29 2007-02-01 Curt Hendrix Compositions and methods for treating estrogen-dependent diseases and conditions
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
EP1928445A1 (en) 2005-09-16 2008-06-11 Cereuscience AB Method and means of preventing and treating sleep disordered breathing
US7319152B2 (en) 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US20070066628A1 (en) 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
EP1945193A1 (en) 2005-10-06 2008-07-23 Pantec Biosolutions AG Transdermal delivery system for treating infertility
US7550458B2 (en) 2005-10-18 2009-06-23 Bristol-Myers Squibb Company Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US8096940B2 (en) 2005-10-19 2012-01-17 Iversync Ii Llc Reproductive management
JP5449775B2 (ja) 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
AU2006304620A1 (en) 2005-10-19 2007-04-26 Scott Josephson Improved reproductive management
EP1952162A2 (en) 2005-10-24 2008-08-06 Manawatu Biotech Investments Ltd. (Mbil) Ovulation cycle monitoring and management
US20070093548A1 (en) 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1951216A2 (en) 2005-11-22 2008-08-06 SmithKline Beecham Corporation Chemical compounds
CN101370380A (zh) 2005-11-22 2009-02-18 史密丝克莱恩比彻姆公司 化合物
WO2007062067A2 (en) 2005-11-22 2007-05-31 Smithkline Beecham Corporation Chemical compounds
JP2009516695A (ja) 2005-11-22 2009-04-23 スミスクライン ビーチャム コーポレーション 化合物
CN101360488A (zh) 2005-11-22 2009-02-04 史密丝克莱恩比彻姆公司 化合物
US20070116829A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Pharmaceutical Composition with High-Potency Sweetener
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
GB0524961D0 (en) 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
WO2007070875A1 (en) 2005-12-15 2007-06-21 Aerosol Science Laboratories, Inc. Treatment of active infections and related compositions
WO2007070851A2 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20090093440A1 (en) 2005-12-20 2009-04-09 Howard Murad Fragranced Therapeutic Delivery System
CA2634059C (en) 2005-12-22 2015-11-24 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
WO2007071448A2 (en) 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
WO2007076144A2 (en) 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
JP2009522251A (ja) 2005-12-28 2009-06-11 ダブール・ファーマ・リミテッド ナノ粒子医薬組成物に有用な生体適合性、非生物分解性、非毒性ポリマー
KR100750320B1 (ko) 2006-01-04 2007-08-17 학교법인 포항공과대학교 쿠커비투릴을 포함하는 젤
CA2634160C (en) 2006-01-05 2014-04-15 Lifecycle Pharma A/S Disintegrating loadable tablets
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
CA2637608A1 (en) 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
WO2007083984A1 (en) 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
US20100278759A1 (en) 2006-02-08 2010-11-04 Howard Murad Topical Therapeutic Delivery System
AU2007218217A1 (en) 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
CA2640520C (en) 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
US20070207225A1 (en) 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors
CA2645080A1 (en) 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
KR100746962B1 (ko) 2006-04-04 2007-08-07 한국과학기술연구원 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
JP2009532505A (ja) 2006-04-05 2009-09-10 ワイス 局所的なエストロゲン欠損から生じる状態の予防又は治療のための方法
CA2648360A1 (en) 2006-04-07 2007-11-01 Novavax, Inc. Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties
AU2007234724A1 (en) 2006-04-07 2007-10-18 The Johns Hopkins University Compounds, compositions and methods for treating hormone-dependent maladies
WO2007120868A2 (en) 2006-04-14 2007-10-25 Stanley Kepka Bioavailability enhancement of lipophilic drug by use solvent system
US8399012B2 (en) 2006-04-17 2013-03-19 Kimberly-Clark Worldwide, Inc. Degradable therapeutic delivery device
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20080039405A1 (en) 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
US20070254858A1 (en) 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
JP2009536164A (ja) 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー ロール圧密成形した熱分解法二酸化ケイ素の医薬組成物での使用
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20070281008A1 (en) 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
US20070287789A1 (en) 2006-06-07 2007-12-13 Stephen Ray Jones Bleed-resistant colored microparticles
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen
US20070292493A1 (en) 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
WO2008006093A2 (en) 2006-07-06 2008-01-10 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
US20080026062A1 (en) 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
US20080038219A1 (en) 2006-08-07 2008-02-14 Calgenex Corporation Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
US20080085877A1 (en) 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080038350A1 (en) 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
US20080095831A1 (en) 2006-08-10 2008-04-24 Mc Graw Thomas L Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent
JP2010502690A (ja) 2006-09-08 2010-01-28 フォーミックス エルティーディー． 有色または着色可能発泡性組成物
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
WO2008031631A2 (en) 2006-09-16 2008-03-20 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
WO2008040488A1 (en) 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
EP2174938A1 (en) 2006-10-12 2010-04-14 SuperGen, Inc. Quinoline derivatives for modulating DNA methylation
US20100168228A1 (en) 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
WO2008084286A2 (en) 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080103116A1 (en) 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US7829116B2 (en) 2006-11-14 2010-11-09 Momentive Performance Materials Inc. Adhesive-forming composition and blend of adhesives obtained therefrom
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
AU2007325207A1 (en) 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
US20080145423A1 (en) 2006-12-14 2008-06-19 Ajmal Ali Khan Chewable tablet and method of formulating
DK2111401T3 (da) 2006-12-20 2011-05-30 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer
WO2008079898A1 (en) 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
EP2104489A2 (en) 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
NZ578883A (en) 2007-01-11 2012-05-25 Acrux Dds Pty Ltd Open top applicator for spreading liquid on skin
CL2008000095A1 (es) 2007-01-12 2008-05-16 Wyeth Corp Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
WO2008091855A1 (en) 2007-01-22 2008-07-31 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
IL181217A0 (en) 2007-02-08 2007-07-04 Haim Levy Pharmaceuticalcompositions based on a microemulsion
WO2008121447A1 (en) 2007-02-14 2008-10-09 Northwestern University Self-assembling membranes and related methods thereof
JP2011512164A (ja) 2007-02-20 2011-04-21 ガルデルマ・リサーチ・アンド・デヴェロップメント 皮膚内への治療物質の送達方法
US20080206156A1 (en) 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
WO2008106149A1 (en) 2007-02-28 2008-09-04 Children's Medical Center Corporation Methods for predicting the onset of menarche
US20080214512A1 (en) 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
SI2148681T1 (sl) 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
EP1988098A1 (en) 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
WO2008140794A1 (en) 2007-05-11 2008-11-20 The Texas A & M University System Hormone normalization therapy and uses thereof
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US20080312198A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
US20080312197A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
ATE537833T1 (de) 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
ES2310968B1 (es) 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
EP2170276B1 (en) 2007-06-26 2018-08-22 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs
EP2170376A1 (en) 2007-06-27 2010-04-07 Samos Pharmaceuticals, Llc Multi-day delivery of biologically active substances
FR2918277B1 (fr) 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
KR100937625B1 (ko) 2007-08-10 2010-01-20 주식회사 제닉 가용성 웹 공극필름 및 이의 제조방법
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20090060997A1 (en) 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8617100B2 (en) 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
EP2205236A4 (en) 2007-09-06 2012-08-22 Regain Biotechnology Pvt Ltd NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
US8507467B2 (en) 2007-09-20 2013-08-13 Shiseido Company, Ltd. Transdermally absorbable preparation
US8741329B2 (en) 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
NZ584275A (en) 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
US20090099149A1 (en) 2007-10-11 2009-04-16 Wyeth Bioadhesive film
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
EP2211866A1 (en) 2007-10-25 2010-08-04 Lupin Limited Antiemetic-oral contraceptive combination
ES2494853T3 (es) 2007-11-02 2014-09-16 Acrux Dds Pty Ltd Sistema de administración transdérmica
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
CA2744906A1 (en) 2007-11-29 2009-06-04 Gregg A. Jackson Progesterone-containing compositions and devices
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
FR2924942B1 (fr) 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
US8762865B2 (en) 2007-12-19 2014-06-24 The Iams Company Interactive survey feedback tool
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB0802403D0 (en) 2008-02-08 2008-03-12 Probiox Sa Compositions for the treatment of oxidative stress
WO2009111574A2 (en) 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
US20090232897A1 (en) 2008-03-14 2009-09-17 Bijayananda Sahoo Pharmaceutical compositions comprising conjugated estrogens
CA2721072A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
WO2009128692A1 (es) 2008-04-14 2009-10-22 Posi Visionary Solutions Llp Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
AU2009240586A1 (en) 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US20090285869A1 (en) 2008-05-14 2009-11-19 Humco Holding Group, Inc. Salt stable lecithin organogel composition
JP2011523704A (ja) 2008-05-20 2011-08-18 カンタイマー，インコーポレイティド イオン交換によって生体液試料を分析するための方法、システム、及び装置
US8349610B2 (en) 2008-05-20 2013-01-08 Cantimer, Inc. Methods, systems and devices for analyzing a surfactant-treated biological fluid sample
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
WO2009158584A1 (en) 2008-06-27 2009-12-30 Wyeth Dual adhesive technology
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
US20110190201A1 (en) 2008-07-24 2011-08-04 Searete Llc Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100028360A1 (en) 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
IT1392903B1 (it) 2008-07-29 2012-04-02 Marino Salin Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
TW201008569A (en) 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
EP2977469A1 (en) 2008-08-28 2016-01-27 Dermtech International Determining age ranges of skin samples
JP5792066B2 (ja) 2008-09-08 2015-10-07 ホフマン／バーレット， リミテッド ライアビリティ カンパニー ポルフィラジン並びに光学的及びデュアル光学的／ｍｒコントラスト並びに治療薬
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
JP6002385B2 (ja) 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法
JP2012502988A (ja) 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
EP2174650A1 (en) 2008-10-08 2010-04-14 Polichem SA Modified release emulsions for application to skin or vaginal mucosa
EP2349201B1 (en) 2008-10-30 2014-10-29 Medlite As Formulation for treatment of vaginal dryness
CN102203117A (zh) 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
EP2218447B1 (en) 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
US20110300167A1 (en) 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
US20110294738A1 (en) 2008-11-04 2011-12-01 Yong Ren Pthr1 receptor compounds
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
WO2010053546A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Crf1 receptor compounds
CN102209531B (zh) 2008-11-14 2014-08-27 梨花女子大学校产学协力团 高分子微球的制造方法和通过该方法制造的高分子微球
US8394759B2 (en) 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
US8222237B2 (en) 2008-11-25 2012-07-17 Evestra, Inc. Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
CN102281870B (zh) 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
WO2010080543A1 (en) 2008-12-18 2010-07-15 Guthery B Eugene Acne vulgaris treatment regimen
US20110318431A1 (en) 2008-12-30 2011-12-29 Endogenx Pharmaceutical Compositions and Methods of Treating Neurological Insults
US8980840B2 (en) 2009-01-13 2015-03-17 Schepens Eye Research Institute Therapeutic modulation of vaginal epithelium boundary lubrication
US20120046518A1 (en) 2009-01-26 2012-02-23 Jennifer Yoakum Estrus Synchronization Preparations & Effective CIDR-Less Protocols
EP2391358A1 (en) 2009-01-27 2011-12-07 Wisconsin Alumni Research Foundation Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
WO2010088409A2 (en) 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010093834A2 (en) 2009-02-12 2010-08-19 Incube Labs, Llc Skin penetrating device and method for subcutaneous solid drug delivery
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US8202736B2 (en) 2009-02-26 2012-06-19 The Governing Council Of The University Of Toronto Method of hormone extraction using digital microfluidics
US20120015350A1 (en) 2009-03-10 2012-01-19 Northwestern University Lateral flow strip and uses thereof
WO2010107922A1 (en) 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
CA2755828A1 (en) 2009-03-17 2010-09-23 Intervet International B.V. Zoo-technical drug delivery device
US9005608B2 (en) 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
EP2419398A4 (en) 2009-04-14 2012-11-28 Infiniton Ab PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
EP2419138A4 (en) 2009-04-14 2013-08-21 Medortus Uk Ltd GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
US8694358B2 (en) 2009-04-14 2014-04-08 Vital Insights Inc. Systems, methods, and media for survey management
US8344007B2 (en) 2009-04-23 2013-01-01 The Hong Kong Polytechnic University Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
US20120128654A1 (en) 2009-04-23 2012-05-24 University Of Cincinnati Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
US8568374B2 (en) 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system
CN102438452B (zh) 2009-05-08 2015-02-25 乔治亚州大学研究基金会 包含cdk抑制剂的化合物和组合物以及用于癌症治疗的方法
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
BRPI1012170A2 (pt) 2009-05-20 2016-03-29 Lingual Consegna Pty Ltd formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
US8658628B2 (en) 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US8815261B2 (en) 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
CN102458386B (zh) 2009-06-23 2016-04-06 拜耳知识产权有限责任公司 用于紧急避孕的药物组合物
FR2947178B1 (fr) 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
WO2011000210A1 (zh) 2009-07-01 2011-01-06 润和生物医药科技(汕头)有限公司 促渗剂组合物及其透皮给药系统中的应用
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US8618083B2 (en) 2009-07-31 2013-12-31 Duquesne University Of The Holy Spirit Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
KR101118587B1 (ko) 2009-08-17 2012-06-12 포항공과대학교 산학협력단 감응성 고분자 캡슐 및 그 제조방법
US8577716B2 (en) 2009-09-17 2013-11-05 Therapeuticsmd, Inc. System and method of ongoing evaluation reporting and analysis
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US8882748B2 (en) 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20110086825A1 (en) 2009-10-13 2011-04-14 Chatroux Sylvia S Therapeutic vaginal emollient
CA2814237A1 (en) 2009-10-15 2011-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Water soluble drug-solubilizer powders and their uses
CN102573946A (zh) 2009-10-16 2012-07-11 汉莫堤克股份有限公司 涂布导管球囊的组合物的用途和经涂布导管球囊
WO2011049948A2 (en) 2009-10-19 2011-04-28 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP2506867B1 (en) 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
WO2011073995A2 (en) 2009-12-14 2011-06-23 Lincoln Pharmaceuticals Limited Liquid vaginal spray of progesterone
EP2512486B1 (en) 2009-12-17 2017-06-28 The Population Council, Inc. Nestorone®/estradiol transdermal gel
EP2512516B1 (en) 2009-12-18 2016-02-17 The Governing Council Of The University Of Toronto Injectable polymer composition for use as a cell delivery vehicle
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
BRPI1001367A2 (pt) 2010-01-04 2012-07-17 Theraskin Farmaceutica Ltda composição para aplicação tópica
TWI482645B (zh) 2010-01-07 2015-05-01 Teikoku Seiyaku Kk 含有待克菲那（ｄｉｃｌｏｆｅｎａｃ）羥乙基吡咯啶之外用油性敷貼劑
US8709451B2 (en) 2010-01-20 2014-04-29 University Of Utah Research Foundation Stable nanoemulsions for ultrasound-mediated drug delivery and imaging
US9162014B2 (en) 2010-01-25 2015-10-20 Concept Medical Research Private Limited Method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent
EP3689364A1 (en) 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
EP2533798A2 (en) 2010-02-09 2012-12-19 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
WO2011102684A2 (ko) 2010-02-22 2011-08-25 영남대학교 산학협력단 태반 추출물을 포함하는 조성물
CA2829180C (en) 2010-03-05 2019-01-15 Newagriculture, Inc. Leaf protein-lipid-soluble material complexes
CA2789238C (en) 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US20130023823A1 (en) 2010-03-10 2013-01-24 University Of Florida Research Foundation Inc. Implantable therapeutic device and methods of making
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
DE102010003494A1 (de) 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
US20110250259A1 (en) 2010-04-12 2011-10-13 Kevin Buckman Method of treating and preventing breast diseases and breast cancer with medicated formula
AU2011240843A1 (en) 2010-04-13 2012-12-06 Johns Hopkins University Methods for treatment of sleep-related breathing disorders
US20130137664A1 (en) 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
WO2011149595A1 (en) 2010-05-28 2011-12-01 Nexgen Dermatologics, Inc. Combination therapy for skin disorders
CN102258455B (zh) 2010-05-28 2014-09-17 上海市计划生育科学研究所 一种甾体激素类涂膜剂及其制备方法
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
JP2012020991A (ja) 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
EP2399566A1 (en) 2010-06-28 2011-12-28 Laboratoire HRA Pharma Once-a-month method of contraception
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
EP2407157A1 (en) 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
KR20120011344A (ko) 2010-07-21 2012-02-08 에스케이케미칼주식회사 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
WO2012024361A1 (en) 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
ES2377616B1 (es) 2010-09-01 2013-02-13 M. Cristina Fernández Rodríguez Composición estabilizante para formulaciones de aplicación tópica y utilización de la misma.
US8435972B2 (en) 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
BRPI1003661A2 (pt) 2010-09-15 2013-01-08 Libbs Farmacêutica Ltda associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
US20120064135A1 (en) 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
ES2386177B1 (es) 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
DE102010047714A1 (de) 2010-10-06 2012-04-12 Justus-Liebig-Universität Derivate von Steroidbenzylaminen mit antiparasitärer, antibakterieller, antimykotischer und/oder antiviraler Wirkung
US20120101073A1 (en) 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases
WO2012055814A1 (en) 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv
WO2012056822A1 (ja) 2010-10-26 2012-05-03 小松精練株式会社 多孔質セラミックス焼結体
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
US9149537B2 (en) 2010-11-04 2015-10-06 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of traumatic brain injury
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
JP6030067B2 (ja) 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的クリーム組成物および使用法
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
KR101424163B1 (ko) 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
DE102011002934A1 (de) 2011-01-20 2012-07-26 Bayer Schering Pharma Ag CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
KR20140004186A (ko) 2011-01-24 2014-01-10 안테리오스, 인코퍼레이티드 표면활성제 조성물
KR101376237B1 (ko) 2011-01-25 2014-03-21 전북대학교산학협력단 사이클릭 에이디피 라이보스와 그 유도체 및 ｃｄ３８을 이용한 수정능 조절 방법
WO2012102254A1 (ja) 2011-01-25 2012-08-02 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩
TW201309670A (zh) 2011-01-25 2013-03-01 Kissei Pharmaceutical 吲哚衍生物或其藥理學上容許之鹽
US20140031323A1 (en) 2011-02-15 2014-01-30 Ramiro M. Perez Transdermal hormone composition and combined static-cyclic delivery
EP2675914A1 (en) 2011-02-18 2013-12-25 Yale University, Inc. The kras-variant and endometriosis
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP2014515008A (ja) 2011-03-03 2014-06-26 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
JP6046644B2 (ja) 2011-03-04 2016-12-21 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ ホルモン補充療法のためのカプセル化された細胞
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
WO2012127501A2 (en) 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
EP2691114A1 (en) 2011-03-29 2014-02-05 Principium Europe S.r.l. Delivery of large molecular weight biologically active substances
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
KR102568894B1 (ko) 2011-05-15 2023-08-21 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
KR101481859B1 (ko) 2011-05-20 2015-01-14 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자의 제조방법 및 그 방법에 의해 제조된 고분자 미립자
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
WO2012166909A1 (en) 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases
CN103747765B (zh) 2011-06-06 2016-04-06 橡冠科学研究院 采用芯吸释放窗口的药物递送装置
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2717880B1 (en) 2011-06-13 2016-12-14 Parthenogen SAGL Selective cns delivery of mifepristone (ru486) to modulate the timing of the spontaneous lh surge during follicular stimulation cycles
US20130004619A1 (en) 2011-06-28 2013-01-03 Kemin Industries, Inc. Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability
CA2842277C (en) 2011-07-20 2020-11-03 Perrigo Israel Pharmaceuticals Ltd Topical oily foam compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR101302557B1 (ko) 2011-08-16 2013-09-02 충북대학교 산학협력단 생리활성물질 함유 미세입자를 포함하는 약물전달계가 고정화된 고분자 생체 재료의 제조방법
WO2013025449A1 (en) 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2744771B1 (en) 2011-08-19 2020-10-21 The Trustees of Princeton University C-halogen bond formation
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
WO2013044067A1 (en) 2011-09-23 2013-03-28 Trustees Of Tufts College Methods for treatment of cervical insufficiency
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
EA201490746A3 (ru) 2011-10-07 2016-09-30 Флорида Стейт Юниверсити Рисеч Фондэйшн Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
US8721331B2 (en) 2011-10-11 2014-05-13 Puthalath Koroth Raghuprasad Oral transmucosal drug delivery device
US9828458B2 (en) 2011-10-17 2017-11-28 Temple University—Of the Commonwealth System of Higher Education Silica particles coated with β-cyclodextrin for the removal of emerging contaminants from wastewater
US9120766B2 (en) 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
WO2013063279A1 (en) 2011-10-25 2013-05-02 The Trustees Of Princeton University A high-loading nanoparticle-based formulation for water-insoluble steroids
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
JP2014532685A (ja) 2011-11-04 2014-12-08 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １８−メチル−６，７−メチレン−３−オキソ−１７−プレグナ−４−エン−２１，１７β−カルボラクトン、該化合物を含有する医薬製剤、および子宮内膜症の治療におけるその使用
KR20140088199A (ko) 2011-11-04 2014-07-09 애자일 쎄라퓨틱스, 인크. 경피 전달 조성물 및 방법
EP2780316B1 (en) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
US20130122051A1 (en) 2011-11-15 2013-05-16 Pharmaceutics International, Inc. Methods of preparing progesterone pharmaceutical compositions
US20120128683A1 (en) 2011-11-22 2012-05-24 Shantha Totada R Autism treatment
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9334538B2 (en) 2011-12-06 2016-05-10 Annabelle Rodriguez Oquendo Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment
EP2788028B1 (en) 2011-12-08 2019-03-27 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
KR101278204B1 (ko) 2011-12-22 2013-06-27 경북대학교 산학협력단 다중 약물전달계를 갖는 생체의료용 금속합금 재료의 제조방법
US9282995B2 (en) 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
CN104254540A (zh) 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
MX367596B (es) 2012-01-26 2019-08-27 Therapeuticsmd Inc Tratamientos transdermicos de sustitucion hormonal.
US20130211351A1 (en) 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
US20130225412A1 (en) 2012-02-28 2013-08-29 Soroush Sardari Lodriche Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment
JP2015508791A (ja) 2012-02-29 2015-03-23 ビー．ブラウン メルズンゲン アーゲーＢ．Ｂｒａｕｎ Ｍｅｌｓｕｎｇｅｎ Ａｇ オキアミリン脂質を含むホルモン含有乳剤
FR2988609B1 (fr) 2012-03-30 2015-09-04 Commissariat Energie Atomique Formulation pour l'hormonotherapie
FR2988610B1 (fr) 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
CN104303058A (zh) 2012-04-18 2015-01-21 西门子医疗保健诊断公司 用于制备缀合物试剂的化合物和方法
EP2846755A1 (en) 2012-05-09 2015-03-18 SiO2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
KR102034330B1 (ko) 2012-05-22 2019-10-18 히타치가세이가부시끼가이샤 슬러리, 연마액 세트, 연마액, 기체의 연마 방법 및 기체
US20130317315A1 (en) 2012-05-22 2013-11-28 Tony V. Lu Method of age management
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP3909586A1 (en) 2012-06-18 2021-11-17 TherapeuticsMD, Inc. Soluble estradiol capsule for vaginal insertion
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2014004424A1 (en) 2012-06-26 2014-01-03 Temple University - Of The Commonwealth System Of Higher Education Method for detecting injury to the brian
SG11201408658PA (en) 2012-06-27 2015-02-27 Medincell Biodegradable drug delivery for hydrophobic compositions
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014012117A1 (en) 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150272934A1 (en) 2012-07-25 2015-10-01 Sova Pharmaceuticals, Inc. Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
PT2877184T (pt) 2012-07-27 2019-12-02 Glia Llc Composições e tratamento para doenças e distúrbios oculares
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
KR101480363B1 (ko) 2012-07-30 2015-01-09 한국과학기술연구원 분해 속도 조절이 가능한 이온기를 가지는 포스파젠계 고분자, 그의 제조방법 및 그의 용도
AU2013305563B2 (en) 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
EP2708213A1 (en) 2012-09-13 2014-03-19 PAT&Co bvba Multipurpose ethylene vinyl acetate fibrous drug delivery systems for long-term implantation or insertion
WO2014052792A1 (en) 2012-09-28 2014-04-03 Sio2 Medical Products, Inc. Halogenated or parylene polymer coating
EP2716291B1 (en) 2012-10-08 2019-11-27 Universität Ulm Combination of opioids and anticancer drugs for cancer treatment
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
WO2014066442A2 (en) 2012-10-24 2014-05-01 Emory University Methods of managing childhood cerebral injury
US20140127185A1 (en) 2012-11-02 2014-05-08 Emory University Methods and compositions using neuroprotective steroids and thrombolytic agents
EP2916869A1 (en) 2012-11-09 2015-09-16 Celgene Corporation Methods for the treatment of bone loss
WO2014076569A2 (en) 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
EP2732824A1 (en) 2012-11-16 2014-05-21 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non human mammals using alpha-beta-linked follicle stimulating hormone
WO2014081598A1 (en) 2012-11-20 2014-05-30 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of endometriosis and related conditions
US20180221389A1 (en) 2016-12-05 2018-08-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2931274A1 (en) 2012-12-11 2015-10-21 Metabolic Solutions Development Company LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US20190022107A1 (en) 2017-06-08 2019-01-24 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20200155465A9 (en) 2012-12-21 2020-05-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9498539B2 (en) 2012-12-27 2016-11-22 Molly Sandra Shoichet Affinity-based controlled release system
US20140186332A1 (en) 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US20140370084A1 (en) 2013-06-18 2014-12-18 Therapeuticsmd, Inc. Estradiol formulations and therapies
WO2015073177A1 (en) 2013-10-10 2015-05-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20170281647A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180123165A (ko) 2016-04-01 2018-11-14 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US20180280410A1 (en) 2017-04-03 2018-10-04 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Also Published As

Publication number Publication date
US9301920B2 (en) 2016-04-05
JP2015520237A (ja) 2015-07-16
US20230218636A1 (en) 2023-07-13
MX383208B (es) 2025-03-13
US20250325561A1 (en) 2025-10-23
CA2876977A1 (en) 2013-12-27
JP2018024688A (ja) 2018-02-15
WO2013192251A1 (en) 2013-12-27
RU2015100533A (ru) 2016-08-10
EP2861072A4 (en) 2015-12-23
US11166963B2 (en) 2021-11-09
AU2017206262A1 (en) 2017-08-10
IL236358B (en) 2022-03-01
PT2861072T (pt) 2024-01-23
US20150224117A1 (en) 2015-08-13
IL236358A0 (en) 2015-02-26
AU2019204655B2 (en) 2021-07-01
US8933059B2 (en) 2015-01-13
US20140100206A1 (en) 2014-04-10
PL2861072T3 (pl) 2024-03-25
ES2967709T3 (es) 2024-05-03
JP6334519B2 (ja) 2018-05-30
US20150224118A1 (en) 2015-08-13
US20190343845A1 (en) 2019-11-14
KR102177782B1 (ko) 2020-11-11
US20130338123A1 (en) 2013-12-19
AU2019204655A1 (en) 2019-07-18
JP2019214598A (ja) 2019-12-19
KR20230021170A (ko) 2023-02-13
US20200281940A1 (en) 2020-09-10
AU2021240253A1 (en) 2021-10-28
EP2861072A1 (en) 2015-04-22
AU2013277236B2 (en) 2017-04-20
BR112014031910B1 (pt) 2021-12-14
US8987238B2 (en) 2015-03-24
EP2861072B1 (en) 2023-10-18
JP7198177B2 (ja) 2022-12-28
RU2019142696A (ru) 2020-02-26
MX2020013533A (es) 2021-02-26
US20140094441A1 (en) 2014-04-03
US11110099B2 (en) 2021-09-07
KR20150028302A (ko) 2015-03-13
US20160213685A1 (en) 2016-07-28
AU2013277236A1 (en) 2015-01-22
US20140100205A1 (en) 2014-04-10
US20150359737A1 (en) 2015-12-17
US11529360B2 (en) 2022-12-20
KR20210107915A (ko) 2021-09-01
US20190142844A1 (en) 2019-05-16
US20140100204A1 (en) 2014-04-10
US10675288B2 (en) 2020-06-09
KR20200128214A (ko) 2020-11-11
BR112014031910A2 (pt) 2017-06-27
US9012434B2 (en) 2015-04-21
MX2014015898A (es) 2015-03-03
EP4309646A1 (en) 2024-01-24
US9006222B2 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
US20250325561A1 (en) Natural Combination Hormone Replacement Formulations and Therapies
US8993548B2 (en) Natural combination hormone replacement formulations and therapies
AU2012340589B2 (en) Natural combination hormone replacement formulations and therapies

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220531

Application number text: 1020217027152

Filing date: 20210825

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220630

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220727

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230404

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220727

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I